Daiichi Sankyo (OTCMKTS:DSNKY) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $17.76 and traded as low as $16.4250. Daiichi Sankyo shares last traded at $16.47, with a volume of 89,263 shares changing hands.

Analysts Set New Price Targets

Several research analysts have recently weighed in on DSNKY shares. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.

Daiichi Sankyo Trading Up 1.6%

The firm has a market cap of $30.85 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.73 and a beta of -0.11. The business’s 50-day moving average is $17.78 and its two-hundred day moving average is $17.69. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.